Tripos International Announces Availability of its Popular SYBYL® Molecular Modeling Environment for the Mac
ST. LOUIS–(BUSINESS WIRE)–Tripos International, leading provider of drug discovery informatics products and services, today announced the release of its popular SYBYL software for Mac OS X Leopard. SYBYL, a suite of computational chemistry and molecular modeling solutions, provides life science researchers with a fully integrated family of applications that help produce and optimize lead candidates, smooth and simplify workflows, and accelerate the pace of molecular discovery.
In making the announcement, Tripos’ General Manager, Patrick Flanagan, said, “The popularity of SYBYL and the increasing use of Mac platforms in molecular discovery facilities made this a natural evolution for Tripos. Using applications built into Mac OS X like iChat, SYBYL users can communicate and collaborate instantly with colleagues in another building or around the world. The computational power of the Mac, and the ability to utilize multiple processors to speed compute-intensive tasks, further enhances the productivity of SYBYL users. SYBYL’s performance on the Mac is impressive – and the ease of use enabled by Mac OS X facilitates the free flow of ideas in molecular discovery research projects. Whether it’s making SYBYL accessible to the large installed base of Mac platforms already in commercial and academic environments or integrating it with new Mac installations, this is an important step in expanding discovery capability for our clients.”
“The reliability, stability and security of Mac OS X Leopard is the perfect fit for users in the scientific community,” said Ron Okamoto, Apple’s vice president of Worldwide Developer Relations. “Bringing Tripos’ SYBYL to the Mac gives our users a significant advantage in the drug discovery field.”
To run SYBYL, Mac users need an Intel-based Mac running the latest version of Mac OS X Leopard.
For more information about SYBYL for Mac OS X, go to www.tripos.com/sybyl .
About the New Tripos International
Tripos International is a global leader in innovative scientific solutions that enable life science researchers to improve the efficiency of their molecular discovery efforts. Established in 1979, Tripos was the first company to bring scientific computational drug discovery capabilities to the pharmaceutical, chemical and food design industries, and today helps a broad range of companies and research facilities accelerate the identification and optimization of new compounds that have the potential to become new products in the drug, food, flavoring and fragrance markets. Headquartered in St. Louis, Missouri, Tripos International serves more than 1,000 customers spanning over 46 countries. Tripos is wholly owned by Vector Capital, a San Francisco-based private equity boutique specializing in buyouts, spinouts and recapitalizations of established technology businesses.
